科伦药业：两款ADC药物获突破性成果

Core Insights - The company announced significant clinical research results at the 2025 European Society for Medical Oncology (ESMO) conference, showcasing advancements in cancer treatment [1] Group 1: Clinical Research Results - The drug sac-TMT demonstrated a median progression-free survival (PFS) of 8.3 months in the randomized, multicenter Phase 3 OptiTROP-Lung04 study for treating EGFR-mutant non-small cell lung cancer (NSCLC), significantly improving compared to the chemotherapy group, with a 51% reduction in the risk of disease progression or death [1] - In the randomized, multicenter Phase 3 OptiTROP-Breast02 study for locally advanced or metastatic hormone receptor-positive and HER2-negative breast cancer, sac-TMT significantly extended the median PFS to 8.3 months, with an objective response rate of 41.5% [1] - The drug bodu-TM compared to emtansine (T-DM1) in a randomized Phase 3 study for HER2-positive metastatic breast cancer showed a significant extension of median PFS to 11.1 months, with an objective response rate reaching 76.9% [1]